drugset / Trial / NCT01160926
Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial
Phase 1
Terminated
31 enrolled
The Christie NHS Foundation Trust
AstraZeneca · collabCancer Research UK · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
To determine the maximum tolerated dose (MTD) of AZD6244 or AZD2171 when combined with pre-operative capecitabine and radiotherapy in patients with locally advanced rectal cancer.
Timeline
- Start
- 2010-07
- Primary completion
- 2013-10
- Completion
- 2016-11-04
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cediranib | Small molecule | 15 mg | Oral |
| Subject | Cediranib | Small molecule | 20 mg | Oral |
| Subject | Cediranib | Small molecule | 30 mg | Oral |
| Subject | Selumetinib | Small molecule | 50 mg | — |
| Subject | Selumetinib | Small molecule | 75 mg | — |